Drug intelligence / Profile preview

cetuximab + envafolimab + mFOLFOXIRI

Development stage: Preclinical
Lead developer: Eli Lilly
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy regimen consisting of cetuximab (an EGFR inhibitor monoclonal antibody), envafolimab (an immune checkpoint inhibitor), and mFOLFOXIRI (a modified chemotherapy regimen containing oxaliplatin, irinotecan, folinic acid, and 5-fluorouracil). This combination likely targets multiple pathways in cancer treatment, including EGFR signaling, immune checkpoint inhibition, and DNA synthesis disruption.

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)CD274 (Programmed cell death protein 1 ligand 1)TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)

Beyond the preview

Go deeper on cetuximab + envafolimab + mFOLFOXIRI.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cetuximab + envafolimab + mFOLFOXIRI.

Explore the full profile